Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells
BMC Cancer, 2012 Background The mammalian target of rapamycin (mTOR) is frequently activated in colon cancers due to mutations in the phosphatidylinositol 3-kinase (PI3K) pathway.
Blaser Benjamin +6 more
doaj +1 more source
mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
Cell & Bioscience, 2020 Mammalian target of rapamycin (mTOR) regulates cell proliferation, autophagy, and apoptosis by participating in multiple signaling pathways in the body. Studies have shown that the mTOR signaling pathway is also associated with cancer, arthritis, insulin
Zhilin Zou +3 more
doaj +1 more source
Turkish Journal of NephrologyBackground: Dysfunction of the mammalian target of the rapamycin (mTOR) signaling pathway by mTOR inhibitors in kidney transplant recipients (KTRs) may contribute to sarcopenia in addition to metabolic factors and infammation.
Merve Güner +11 more
doaj +1 more source
Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells [PDF]
, 2009 Background Treatment options for metastatic renal cell carcinoma (RCC) are limited due to resistance to chemo- and radiotherapy. The development of small-molecule multikinase inhibitors have now opened novel treatment options.
Natsheh, Iyad Y. M. +15 more
core +2 more sources
Hypoxia-induced signaling in angiogenesis : role of mTOR, HIF and Angiotensin II [PDF]
, 2007 This thesis includes the work of four different projects I have been following during my time as a PhD student; (1) the characterization of mTOR-associated signaling and endothelial cell proliferation in response to hypoxia, and (2) identification of ...
Petrimpol, Marco Renato
core +1 more source
Regulation of the mTOR/S6K pathway by cellular energy [PDF]
, 2009 The mammalian target of rapamycin (mTOR) signaling pathway integrates positive and negative signals that control cellular growth, metabolism and survival. mTOR exists in two different complexes, mTOR Complex1 and mTOR Complex2.
Kalender, Adem
core +1 more source
The Bumpy Road towards mTOR Inhibition in Glioblastoma: Quo Vadis?
Biomedicines, 2021 Glioblastoma multiforme (GBM), a grade IV astrocytoma, is a lethal brain tumor with a poor prognosis. Despite recent advances in the molecular biology of GBM, neuro-oncologists have very limited treatment options available to improve the survival of GBM ...
Kostas A. Papavassiliou +1 more
doaj +1 more source
Solid Pseudopapillary Neoplasm of the Pancreas in Children and Adolescents: Expert Recommendations
Pediatric Blood &Cancer, EarlyView.ABSTRACT Solid pseudopapillary neoplasm of the pancreas (SPN) is a rare low‐grade malignant exocrine pancreatic tumor, mostly discovered during the second decade of life in females, with a very good prognosis, provided microscopically complete surgical excision is achieved.
Sabine Irtan +18 more
wiley +1 more source
mTOR Inhibitors as Radiosensitizers in Neuroendocrine Neoplasms [PDF]
Frontiers in Oncology, 2020 Peptide receptor radioligand therapy (PRRT) has evolved as an important second-line treatment option in the management of inoperable and metastatic neuroendocrine neoplasms (NEN). Though high radiation doses can be delivered to the tumors, complete remission is still rare. Radiosensitization prior to PRRT is therefore considered to
Samantha Exner +7 more
openaire +4 more sources
Mammalian target of rapamycin inhibitors: A paradigm shift in current immunosuppression protocols
Indian Journal of Transplantation, 2016 Immunosuppression is an obligate necessity in kidney transplant. However, the standard immunosuppression causes chronic deterioration of allograft function over long term use. Mammalian target of rapamycin (mTOR) inhibitors provide an alternative in such
Indranil Ghosh, Manish Rathi
doaj +1 more source